The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial decrease in body weight and enhance metabolic function, par